Pulmonary metastases are usually seen as parenchymal nodules, lymphatic-interstitial spread and pleural effusion, however cavitary and cystic metastatic lesions are rare. While breast cancer, gastrointestinal tumors, kidney tumors, malignant melanoma, sarcomas, lymphoma and leukemia mostly metastasize to the lung, endometrial adenocarcinoma rarely metastasizes. A 73-year-old woman with multiple cystic-cavitary lung lesions was referred to our clinic because of chronic cough. She had endometrial adenocarcinoma metastasis to the lung. We wanted to present our case because of the rare occurrence of cystic-cavitary lung metastases and the rare presentation of metastasis of endometrial carcinomas to the lung.

Download full-text PDF

Source
http://dx.doi.org/10.5578/tt.67686DOI Listing

Publication Analysis

Top Keywords

endometrial adenocarcinoma
8
cystic-cavitary lung
8
lung
5
case endometrium
4
endometrium adenocarcinoma
4
adenocarcinoma multiple
4
multiple cavitary
4
cavitary pulmonary
4
pulmonary metastasis]
4
metastasis] pulmonary
4

Similar Publications

P53-abnormal endometrial carcinomas are high-grade and aggressive tumors which should be treated with chemo-/radiotherapy. In low-grade endometrioid carcinoma (LGEC), abnormal expression of p53 is an exceptional finding and is typically accompanied by patchy p16 positivity and diffuse hormone receptor expression. Herein, we report a case of LGEC exhibiting both p53 and p16 overexpression, highlighting the diagnostic pitfalls related to such phenotype.

View Article and Find Full Text PDF

Clinicopathological Significance of Claudin-6 Immunoreactivity in Low-grade, Early-stage Endometrioid Endometrial Carcinoma.

In Vivo

December 2024

Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

Background/aim: Dysregulation of claudin 6 (CLDN6) expression has been widely documented in various malignancies. CLDN6 is aberrantly expressed in many types of human carcinomas; however, its clinical significance in endometrial carcinoma has seldom been investigated. This study aimed to examine the immunohistochemical expression status of CLDN6 in low-grade, early-stage endometrioid endometrial carcinoma (LGES-EEC) and to assess its clinicopathological significance.

View Article and Find Full Text PDF

CYFIP2: potential pancreatic cancer biomarker and immunotherapeutic target.

Discov Oncol

December 2024

The First Affiliated Hospital of Nanchang University, Nanchang University, 17 Yongwai Zhengjie, Donghu District, Nanchang, 330006, People's Republic of China.

Objective: It has been shown that the CYFIP2 (Cytoplasmic FMR1-interacting protein 2) gene is apoptosis p53-dependent and is associated with poor prognosis in malignant tumors such as gastric cancer and other and cervical cancer. However, the prognostic potential of CYFIP2 in pancreatic cancer remains unclear. In this work, we first explain the great potential of CYFIP2 malignant progression from a broader perspective (pan-cancer) and confirm its oncogenic value in pancreatic cancer.

View Article and Find Full Text PDF

Atypical polypoid adenomyoma (APA) is a benign uterine lesion with a premalignant potential and occurs in women of reproductive age. The histological pattern is characterized by irregular epithelial proliferation and muscular stroma. Based on a case report, we performed a systematic review of the literature to assess the main immunohistochemical and molecular markers that contribute to its differential diagnosis against endometrial adenocarcinoma (EC).

View Article and Find Full Text PDF
Article Synopsis
  • Uterine carcinosarcoma (UCS) is a rare cancer combining both carcinoma and sarcoma features, often resembling endometrial carcinoma, with a potential link to nulliparity (never having given birth) as a risk factor.
  • A 55-year-old woman presented with postmenopausal vaginal bleeding and was diagnosed after surgery, revealing well-differentiated adenocarcinoma and osteosarcoma components, along with multiple positive immunohistochemical markers.
  • Following a series of surgical interventions and treatments, including chemotherapy and radiotherapy, the patient demonstrated no signs of tumor recurrence and had a disease-free survival of seven months as of July 2024.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!